References
- Amir SY, Upendra AA, Murali P, et al. (2013). Identification of domperidone metabolites in plasma and urine of gastroparesis patients with LC–ESI-MS/MS. Xenobiotica 43:1073–83
- Asai H, Udaka F, Hirano M, et al. (2005). Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease. Parkinsonism Relat Disord 11:499–502
- Bailey J, Thew M, Balls M. (2013). An analysis of the use of dogs in predicting human toxicology and dog safety. Altern Lab Anim 41:335–50
- Clarke NJ, Rindgen D, Korfmacher WA, et al. (2001). Systematic LC/MS metabolite identification in drug discovery. Anal Chem 73:430A–9A
- Curran MP, Robinson DM. (2008). Mosapride in gastrointestinal disorders. Drugs 68:981–91
- Dai HX, Wang MM, Li XR, et al. (2008). Structural elucidation of in vitro and in vivo metabolites of cryptotanshinone by HPLC–DAD–ESI–MSn. J Pharm Biomed Anal 50:27–34
- Hsieh Y, Korfmacher WA. (2006). Increasing speed and throughput when using HPLC-MS/MS systems for drug metabolism and pharmacokinetic screening. Curr Drug Metab 7:479–89
- Liu Z, Sakakibara R, Odaka T, et al. (2005). Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 20:680–6
- Matsumoto S, Tagawa M, Hatoyama T, et al. (1993a). Absorption, distribution, metabolism and excretion of [carbonyl-14C]mosapride citrate after repeated oral administration in rats. Arzneimittelforschung 43:1103–8
- Matsumoto S, Yoshida K, Itogawa A, et al. (1993b). Metabolism of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys. Arzneimittelforschung 43:1095–102
- Nassar AEF, Talaat RE, Kamel AM. (2006). The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet? Curr Opin Drug Discov Devel 9:61–74
- Oliveira EJ, Watson DG. (2000). Liquid chromatography-mass spectrometry in the study of the metabolism of drugs and other xenobiotics. Biomed Chromatogr 14:351–72
- Pedraglio S, Rozio MG, Misiano P, et al. (2007). New perspectives in bio-analytical techniques for preclinical characterization of a drug candidate: UPLC-MS/MS in in vitro metabolism and pharmacokinetic studies. J Pharm Biomed Anal 44:665–73
- Sakashita M, Yamaguchi T, Miyazaki H, et al. (1993). Pharmacokinetics of the gastrokinetic agent mosapride citrate after single and multiple oral administrations in healthy subjects. Arzneimittelforschung 43:867–72
- Sun XH, Niu LL, Li XQ, et al. (2009a). Characterization of metabolic profile of mosapride citrate in rat and identification of two new metabolites: Mosapride N-oxide and morpholine ring-opened mosapride by UPLC-ESI-MS/MS. J Pharm Biomed Anal 50:27–34
- Sun XH, Man F, Pang LY, et al. (2009b). Fungal biotransformation of mosapride by Cunninghamella elegans. J Mol Catal B: Enzym 59:82–9
- U.S. Food and Drug Administration. (2008). Guidance for industry safety testing of drug metabolites. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079266.pdf [last accessed February 2008]
- Yoshida N. (1999). Pharmacological effects of the gastroprokinetic agent mosapride citrate. Nippon Yakurigaku Zasshi 113:299–307